Aptinyx Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Craig R. Jalbert CIRA
- Full Time Employees
- 12
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 909 Davis Street Evanston IL United States of America 60201
- IPO Date
- Jun 21, 2018
- CIK
- 0001674365
- Website
- aptinyx.com
- Similar Companies
- Business
- Aptinyx Inc. operates as a clinical-stage biopharmaceutical company specializing in the discovery, development, and commercialization of novel, proprietary, synthetic small molecule therapies targeting brain and nervous system disorders. The company’s core product pipeline includes NYX-2925, an oral NMDA receptor modulator in clinical development for chronic pain including neuropathic pain associated with diabetic peripheral neuropathy; NYX-783, an NMDA receptor modulating candidate in clinical trials for opioid use disorder and preclinical development for alcohol use disorder; and NYX-458, designed for cognitive impairment in Parkinson's disease and related dementias. Aptinyx leverages a unique mechanism to modulate NMDA receptors to enhance synaptic plasticity, addressing challenging neurological conditions. Founded in 2015 as a spin-off from Allergan's drug discovery unit and headquartered in Evanston, Illinois, Aptinyx operates primarily in the United States. Recent major developments include securing a $5.6 million grant from the NIH HEAL Initiative to advance clinical studies of NYX-783 for opioid use disorder, reflecting a strategic focus on addiction therapeutics. The company has discontinued development of NYX-458 for cognitive impairment following Phase 2 study results showing lack of clinical efficacy, and halted the Phase 2b study of NYX-2925 for fibromyalgia due to insufficient effectiveness, pivoting its resources accordingly. Aptinyx also completed a significant workforce reduction to lower operational expenses and has strengthened collaboration with Yale University researchers to enhance its NYX-783 development program. These changes underscore a strategic recalibration towards the opioid crisis and leveraging existing clinical assets. Aptinyx primarily targets neurological and psychiatric disease markets with therapies designed to meet unmet medical needs in chronic pain, post-traumatic stress disorder, opioid use disorder, and cognitive impairment. Its product candidates are in various stages of clinical development, supported by FDA Fast Track designations for some indications. With approximately 22 employees, the company maintains a focused investment in research and clinical advancement of small-molecule NMDA modulators within the U.S. biopharmaceutical sector.
Tentarix Biotherapeutics Announces the Appointment of Andrew D. Kidd, MD, CFA, as CEO
Aptinyx Reports on Fourth Quarter and Full Year 2022 Results and Highlights and Review of Strategic Alternatives
Here's Why Aptinyx Inc. (APTX) Is a Great 'Buy the Bottom' Stock Now
COYA, Dr. Reddy's Sign Deal for Proposed Abatacept Biosimilar
Why Is Aptinyx (APTX) Stock Down 64% Today?
Aptinyx Reports Results from Phase 2 Study of NYX-458 in Cognitive Impairment Associated with Parkinson's Disease and Dementia with Lewy Bodies and Provides Pipeline and Corporate Update
Aptinyx to Present at the SVB Securities Global Biopharma Conference
Preclinical Data from Aptinyx's NMDA Receptor Modulators to be Presented at the 52nd Annual Meeting of the Society for Neuroscience
Aptinyx Inc. (APTX) CEO Andy Kidd on Q3 2022 Results - Earnings Call Transcript
Aptinyx Reports Third Quarter 2022 Financial Results and Recent Highlights
Clinical Evaluation of Aptinyx's NYX-783 for Treatment of Opioid Use Disorder to Be Funded by $5.6 Million NIH Grant
Aptinyx to Report Third Quarter 2022 Financial Results on Tuesday, November 8, 2022
Aptinyx to Report Third Quarter 2022 Financial Results on Tuesday, November 8, 2022
Aptinyx Completes Enrollment in Phase 2 Study of NYX-458 in Cognitive Impairment Associated with Parkinson's Disease and Dementia with Lewy Bodies
Aptinyx's (APTX) Mid-Stage Fibromyalgia Study Fails to Meet Goal
Aptinyx Reports Results from Phase 2b Study of NYX-2925 in Fibromyalgia
Aptinyx Inc. (APTX) CEO Andy Kidd on Q2 2022 Results - Earnings Call Transcript
Aptinyx Reports Second Quarter 2022 Financial Results and Recent Highlights
Aptinyx to Report Second Quarter 2022 Financial Results on Thursday, August 4, 2022
Aptinyx to Report Second Quarter 2022 Financial Results on Thursday, August 4, 2022